Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 16;20(1):49.
doi: 10.1186/s40360-019-0327-5.

Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo

Jean-Claude Makenga Bof  1 , Daniel Muteba  2 , Paul Mansiangi  3 , Félicien Ilunga-Ilunga  4   5 , Yves Coppieters  4
Affiliations

Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo

Jean-Claude Makenga Bof et al. BMC Pharmacol Toxicol. .

Abstract

Background: The progress of mass, community-directed, treatment with ivermectin (CDTI) for onchocerciasis control was disrupted by severe adverse effects (SAE) in the Democratic Republic of Congo (DRC). The study aimed at determining the frequency of post-CDTI SAE as well as factors associated with the occurrence of SAE.

Methods: Our retrospective study relied on SAE collection cards, as archived by the DRC Ministry of Health, and compiled for people who benefited from ivermectin treatment then further developed SAE. The study included 945 post-CDTI SAE recorded in DRC between 2003 and 2017. These cases occurred in 15 projects out of 22 projects implemented in the country. All cards were reviewed and analysed.

Results: Between the years 2003 and 2017, the total average population treated was around 15,552,588 among which 945 cases of SAE were registered in DR Congo, i.e. 6 cases of SAE for 100,000 persons treated per year. 55 deaths related to post-CDTI SAE were recorded, which represents 5.8% of all cases of SAE. Non-neurological SAE were dominated by severe headaches (74.8%), myalgia (64.0%) and arthralgia (62.7%). Neurological SAE were mainly coma (94.1%), motor deficit (75.4%) and palpebral subconjunctival haemorrhages (38.8%). Factors associated with the occurrence of SAE were: male, age over 18 years old, alcohol consumption, hemp intake and the presence of loiasis. The study also highlighted weaknesses of the National Program for Onchocerciasis Control (NPOC) in terms of awareness campaigns among the population.

Conclusion: Co-endemicity of loiasis and onchocerciasis is one of the key factors responsible for the occurrence of SAE following ivermectin treatment. Mobilization of resources necessary to the appropriate management of SAE and awareness of populations are essential to achieve onchocerciasis control in DRC.

Keywords: Communities; Community-directed treatment with ivermectin; Democratic Republic of Congo; Ivermectin; Onchocerciasis; Severe adverse effects.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Map of CDTI areas in DRC. Source: [38]
Fig. 2
Fig. 2
Mapping of onchocerciasis and loiasis co-endemicity in DRC. Source: [39]
Fig. 3
Fig. 3
Monitoring of severe adverse effects and deaths after ivermectin treatment in the DRC, between 2003 and 2017
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cheke RA. Factors affecting onchocerciasis transmission: lessons for infection control. Expert Rev Anti-Infect Ther. 2017;4:377–386. doi: 10.1080/14787210.2017.1286980. - DOI - PubMed
    1. Weldegebreal F, Medhin G, Weldegebreal Z, Legesse M. Assessement of community’s knowledge, attitude and pratice about onchocerciasis and community directed treatment with Ivermectin in Quara District, north westem Ethiopia. Parasit Vectors. 2014;7:90–98. doi: 10.1186/1756-3305-7-98. - DOI - PMC - PubMed
    1. Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, Ogbuagu KF, Okello D, Ozoh G, Remme J. Onchocerciasis: the clinical and epidemiologie burden of skin disease in Africa. Ann Top Med Parasitol. 2002;96:283–296. doi: 10.1179/000349802125000826. - DOI - PubMed
    1. Murdoch ME, Murdoch IE, Evans J, Yahaya H, Njepuome N, Cousens S, Jones BR, Abiose A. Pre-control relationship of onchocercal skin disease with onchocercal infection in Guinea savanna. Northern Nigeria PLoS Negl Trop Dis. 2017;11:1–19. - PMC - PubMed
    1. Benton B. Economic impact of onchocerciasis control through the African program for onchocerciasis control: an overview. Ann Trop Med Parasitol. 1998;92:S33–S39. doi: 10.1080/00034983.1998.11813363. - DOI - PubMed

LinkOut - more resources